What is Commonwealth Diagnostics International?
Commonwealth Diagnostics International operates at the intersection of medical technology and gastroenterology, providing a robust suite of at-home, non-invasive breath and blood tests. The company specializes in identifying conditions such as SIBO and IBS, utilizing an ISO 13485-certified and FDA-registered framework to ensure diagnostic precision. Central to its value proposition is the MyGI Gateway, a proprietary platform designed to streamline data management for healthcare providers. By integrating advanced diagnostic technology with intuitive clinical decision-support tools, CDI effectively bridges the gap between patient-centric testing and professional medical oversight, catering to both pediatric and adult demographics.
How much funding has Commonwealth Diagnostics International raised?
Commonwealth Diagnostics International has raised a total of $295K across 2 funding rounds:
Debt
$150K
Debt
$145K
Debt (2020): $150K with participation from PPP
Debt (2021): $145K led by PPP
Key Investors in Commonwealth Diagnostics International
PPP
Public-Private Partnership
What's next for Commonwealth Diagnostics International?
With the recent influx of capital, Commonwealth Diagnostics International is poised to transition into a phase of aggressive market penetration and technological refinement. The strategic roadmap likely involves expanding the MyGI Gateway ecosystem to support broader clinical integration and enhancing the scalability of its diagnostic supply chain. As the firm navigates this late-stage growth cycle, the focus will remain on maintaining rigorous regulatory compliance while scaling its footprint in the global diagnostics market. Future initiatives are expected to prioritize the optimization of patient-provider workflows, ensuring that CDI remains at the forefront of functional gastrointestinal health innovation.
See full Commonwealth Diagnostics International company page
